Monitoring response to antiangiogenic therapy in non–small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI
AJ de Langen, V van den Boogaart… - Journal of Nuclear …, 2011 - Soc Nuclear Med
With antiangiogenic agents, tumor shrinkage may be absent, despite survival benefit. The
present study assessed the predictive value of molecular imaging for the identification of …
present study assessed the predictive value of molecular imaging for the identification of …
Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy
N Tacelli, T Santangelo, A Scherpereel, A Duhamel… - European …, 2013 - Springer
Objectives To determine whether CT can depict early perfusion changes in lung cancer
treated by anti-angiogenic drugs, allowing prediction of response. Methods Patients with …
treated by anti-angiogenic drugs, allowing prediction of response. Methods Patients with …
Exploration of imaging biomarkers for predicting survival of patients with advanced non–small cell lung cancer treated with antiangiogenic chemotherapy
OBJECTIVE. The objective of this study was to compare imaging biomarkers, including 18F-
FDG PET, CT perfusion (CTP), and CT texture analysis (CTTA), in predicting the survival of …
FDG PET, CT perfusion (CTP), and CT texture analysis (CTTA), in predicting the survival of …
[HTML][HTML] Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
JSW Lind, MR Meijerink, AMC Dingemans… - European …, 2010 - Springer
Objective We investigated the feasibility of serial dynamic contrast-enhanced computed
tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer …
tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer …
Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects
Objective: To determine whether CT-perfusion (CT-p) can be used to evaluate the effects of
chemotherapy and anti-angiogenic treatment in patients with non-small-cell lung carcinoma …
chemotherapy and anti-angiogenic treatment in patients with non-small-cell lung carcinoma …
Dual-phase dual-energy CT in patients treated with erlotinib for advanced non-small cell lung cancer: possible benefits of iodine quantification in response …
J Baxa, T Matouskova, G Krakorova, B Schmidt… - European …, 2016 - Springer
Objectives To investigate the relationship of dual-phase dual-energy CT (DE-CT) and
tumour size in the evaluation of the response to anti-EGFR therapy in patients with …
tumour size in the evaluation of the response to anti-EGFR therapy in patients with …
The tumor microenvironment in non–small-cell lung cancer
The tumor microenvironment (TME) of NSCLC is heterogeneous with variable blood flow
through leaky immature vessels resulting in regions of acidosis and hypoxia. Hypoxia has …
through leaky immature vessels resulting in regions of acidosis and hypoxia. Hypoxia has …
Angiogenesis in non-small cell lung cancer: imaging with perfusion computed tomography
Manipulation of tumor vasculature has emerged as a promising therapeutic strategy in
advanced non-small cell lung cancer (NSCLC). Bevacizumab has been licensed for first-line …
advanced non-small cell lung cancer (NSCLC). Bevacizumab has been licensed for first-line …
Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of 18F-FDG Uptake at PET—Association with Treatment Response and Prognosis
GJR Cook, ME O'Brien, M Siddique, S Chicklore… - Radiology, 2015 - pubs.rsna.org
Purpose To determine if first-order and high-order textural features on fluorine 18 (18F)
fluorodeoxyglucose (FDG) positron emission tomography (PET) images of non–small cell …
fluorodeoxyglucose (FDG) positron emission tomography (PET) images of non–small cell …
Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated …
Purpose: Assessing clinical activity of molecularly targeted anticancer agents, especially in
the absence of tumor shrinkage, is challenging. To evaluate on-treatment 18F …
the absence of tumor shrinkage, is challenging. To evaluate on-treatment 18F …